Navigation Links
MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting

GAITHERSBURG, Md., Sept. 23 /PRNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that they will be conducting a Product Demonstration of the MaxCyte STX Scalable Transfection System on Thursday, September 25, 2008, at 10:00AM PDT, at the A/C/T Assays & Cellular Targets Conference in San Diego, California.

According to Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte, "The MaxCyte STX Scalable Transfection System can be used to transfect primary cells, cell lines, and stem cells with a range of molecules, including DNA plasmids, different types of RNA, proteins, etc., with very high efficiency. Over ten billion cells can be transfected in 30 minutes. This scale and capability can greatly improve the productivity of drug discovery laboratories. We are pleased to have the opportunity to demonstrate this technology at the A/C/T Meeting."

"We are very excited that the pharmaceutical industry views the MaxCyte STX technology as key to reducing drug discovery bottlenecks," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. Cells modified using the MaxCyte STX can be used on the research scale and in high-throughput screening assays. The faster you can get to the assay, the more compounds you can screen for biological activity, and the greater your likelihood of finding a successful drug candidate."

After the Product Demonstration, MaxCyte scientists will be available at the A/C/T Meeting to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte STX Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information,

SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte to Present at BIO-Europe Spring 2008 Conference
2. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
5. National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine
6. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
7. PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress
8. Bluestar Silicones Debuts New Soft Elastomers at Medical Device & Manufacturing East Expo
9. International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Post Your Comments:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):